SELLAS Life Sciences Group, Inc. (SLS) stock
SLSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$14.86−3.09 (-17.21%)
Close on Nov 19, 2026Market cap $3.00BP/E –Yield –
SELLAS Life Sciences revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
SELLAS Life Sciences's revenue for the twelve months ending Dec 31, 2023 was $0, down 100.0% year over year. For fiscal 2023 it was $0, down 100.0% from the year before. The highest annual figure on record is $9.32M in fiscal 2014.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $0 | -100.0% |
| FY2022 | Dec 31, 2022 | $1.00M | -86.8% |
| FY2021 | Dec 31, 2021 | $7.60M | +300.0% |
| FY2020 | Dec 31, 2020 | $1.90M | – |
| FY2019 | Dec 31, 2019 | $0 | -100.0% |
| FY2014 | Dec 31, 2014 | $9.32M | +274.7% |
| FY2013 | Dec 31, 2013 | $2.49M | – |
| FY2012 | Dec 31, 2012 | $0 | – |
| FY2011 | Dec 31, 2011 | $0 | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2023 | Dec 31, 2023 | $0 | – |
| Q3 FY2023 | Sep 30, 2023 | $0 | – |
| Q2 FY2023 | Jun 30, 2023 | $0 | – |
| Q1 FY2023 | Mar 31, 2023 | $0 | -100.0% |
| Q4 FY2022 | Dec 31, 2022 | $0 | – |
| Q3 FY2022 | Sep 30, 2022 | $0 | – |
| Q2 FY2022 | Jun 30, 2022 | $0 | -100.0% |
| Q1 FY2022 | Mar 31, 2022 | $1.00M | -82.5% |
| Q4 FY2021 | Dec 31, 2021 | $0 | -100.0% |
| Q3 FY2021 | Sep 30, 2021 | $0 | – |
| Q2 FY2021 | Jun 30, 2021 | $1.90M | – |
| Q1 FY2021 | Mar 31, 2021 | $5.70M | – |
| Q4 FY2020 | Dec 31, 2020 | $1.90M | – |
| Q3 FY2020 | Sep 30, 2020 | $0 | – |
| Q2 FY2020 | Jun 30, 2020 | $0 | – |
| Q1 FY2020 | Mar 31, 2020 | $0 | – |
See a number that looks wrong?